Utilizing left atrial strain to identify patients at risk for atrial fibrillation on ibrutinib

Arushi Singh, Nadia El Hangouche, Katherine McGee, Fei Fei Gong, Robert Lentz, Joseph Feinglass, Nausheen Akhter*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Background: Ibrutinib is associated with atrial fibrillation (AF), though echocardiographic predictors of AF have not been studied in this population. We sought to determine whether left atrial (LA) strain on transthoracic echocardiography could identify patients at risk for developing ibrutinib-related atrial fibrillation (IRAF). Methods: We performed a retrospective review of 66 patients who had an echocardiogram prior to ibrutinib treatment. LA strain was measured with TOMTEC Imaging Systems, obtaining peak atrial longitudinal strain (PALS) and peak atrial contraction strain (PACS) on 4-chamber and 2-chamber views. Statistical analysis was performed with chi-square analysis, t test, or binomial regression analysis, with a P-value <.05 considered statistically significant. Results: Twenty-two patients developed IRAF (33%). Age at initiation of ibrutinib was significantly associated with IRAF (65.1 years vs 74.1 years, P =.002). Mean ibrutinib dose was lower among patients who developed IRAF (388.2 ± 121.7 vs 448.6 ± 88.4, P =.025). E/e′ was significantly higher among patients who developed IRAF (11.5 vs 9.3, P =.04). PALS was significantly lower in patients who developed AF (30.3% vs 36.3%, P =.01). On multivariate regression analysis, age, PALS, and PACS were significantly associated with IRAF. On multivariate regression analysis, only PACS remained significantly associated with IRAF while accounting for age. Conclusions: Age, ibrutinib dose, E/e′, and PALS on pre-treatment echocardiogram were significantly associated with development of IRAF. On multivariate regression analyses, age, PALS, and PACS remained significantly associated with IRAF. Impaired LA mechanics add to the assessment of patients at risk for IRAF.

Original languageEnglish (US)
Pages (from-to)81-88
Number of pages8
Issue number1
StatePublished - Jan 2021


  • B-cell malignancies
  • atrial fibrillation
  • echocardiography
  • ibrutinib
  • left atrial strain
  • tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Utilizing left atrial strain to identify patients at risk for atrial fibrillation on ibrutinib'. Together they form a unique fingerprint.

Cite this